Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study.
Zemanick ET, McColley SA, Linnemann RW, Rayment JH, Harris WT, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Sosnay PR, Ahluwalia N, Liu L, Jennings M, Rosenfeld M
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.